United, Cerep and Panlabs stand stronger

Jenny Thouvenin, Eurofins Cerep-Panlabs, pharma@eurofins.com

In the last quarter of 2012 and beginning of 2013, Eurofins acquired respectively Panlabs and Cerep - the two leaders in the field of molecular pharmacology testing services. Formerly in competition, Cerep and Panlabs have merged within the latest Eurofins' business line, Pharma Discovery Services, thus becoming a major partner in drug discovery services with a portfolio of hundreds of both in vitro and in vivo assays, offering the largest available pharmacological panel for drug screening and profiling.

After over 20 years as Chief Executive Officer at Cerep, Eurofins has entrusted Thierry Jean with the role of managing Eurofins Cerep-Panlabs, as a Senior Vice President.

The merger of both entities enhances valuable existing expertise, knowledge and skills. Moreover, with over 350 people in four operational sites worldwide: Poitiers (France); Seattle, WA (USA); Shanghai (China) and Taipei (Taiwan), Eurofins Cerep-Panlabs offers logistics and functional solutions to perform studies with the highest quality to meet customer needs. From conventional binding assays, to cellular disease models (oncology and immunology, in vitro toxicology) or the highly valued epigenetic targets, Eurofins Cerep-Panlabs covers complete customer requirements in all therapeutic areas. The offer includes high throughput profiling and screening services as well as customised assay development.

While assay catalogues are being harmonised, the sales forces have already joined and contribute daily to the success of the business line. Currently Eurofins Cerep-Panlabs is developing new strategies to provide customers costeffective assays and reduced turnaround times.

Another significant strength of combined entities will be the merger of the two proprietary databases, BioPrint® and Foresight™, allowing anticipation of adverse drug reactions and leading to the identification of most promising drug candidates at early stage.

For more information, please visit www.eurofins.com/pharma